Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olamkicept - Ferring Pharmaceuticals

Next Previous
X
Search
Drug Profile

Olamkicept - Ferring Pharmaceuticals

Alternative Names: FE-301; FE-999301; TJ-301

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Conaris Research Institute
  • Developer Ferring Pharmaceuticals; I-MAB Biopharma; Leading Biopharm
  • Class Anti-inflammatories; Glycoproteins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Ulcerative colitis
  • Phase I Gastrointestinal disorders
  • No development reported Crohn's disease

Most Recent Events

  • 28 Nov 2024 Ferring Pharmaceuticals completes a phase I trial in Inflammatory bowel disorders (In volunteers) in Japan (IV) (NCT06515834)
  • 15 Nov 2024 Ferring Pharmaceuticals completes the phase I trial in Gastrointestinal disorders (In volunteers) in Germany (IV) (NCT06298032)
  • 20 Feb 2024 Phase-I clinical trials in Gastrointestinal disorders (In volunteers) in Germany (IV) (NCT06298032)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top